AI English summary of an SEC filing — figures as filed
Cardinal Health CAHThe company said it updated its organizational structure and re-aligned its operating and reporting segments beginning in the third quarter of fiscal year 2024 Q3. The new reportable segments are Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution.
Key points
AI summaryThe company said it updated its organizational structure and re-aligned its operating and reporting segments beginning in the third quarter of fiscal year 2024 Q3. The new reportable segments are Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution.
The company said it is voluntarily furnishing unaudited recast segment results for each quarter of fiscal years 2022 and 2023 and for the first two quarters of fiscal year 2024. The results are attached as Exhibit 99.1.
The company said the recast segment results are not a restatement of previously issued financial statements and do not affect previously reported consolidated revenue, operating earnings/(loss), net earnings/(loss) or diluted earnings/(loss) per share. It also said the changes reflect the elimination of inter-segment revenue and allocated corporate expenses for shared functions.
The company presented recast full-year fiscal year 2023 Total Segment Revenue of $205,091 million and Total Segment Profit of $2,110 million. Full-year segment revenue for Pharmaceutical and Specialty Solutions was $188,820 million, and segment profit was $1,862 million.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Cardinal Health Reorganizes Operating and Reporting Segments From Fiscal 2024 Q3
The company said it updated its organizational structure and re-aligned its operating and reporting segments beginning in the third quarter of fiscal year 2024 Q3. The new reportable segments are Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution.
Source · Based on the filing body and exhibits
Cardinal Health Provides Recast Segment Results for Fiscal 2022, 2023 and 2024, 1 Through Q2
The company said it is voluntarily furnishing unaudited recast segment results for each quarter of fiscal years 2022 and 2023 and for the first two quarters of fiscal year 2024. The results are attached as Exhibit 99.1.
Source · Based on the filing body and exhibits
Recast Is Not a Restatement of Prior Financial Statements
The company said the recast segment results are not a restatement of previously issued financial statements and do not affect previously reported consolidated revenue, operating earnings/(loss), net earnings/(loss) or diluted earnings/(loss) per share. It also said the changes reflect the elimination of inter-segment revenue and allocated corporate expenses for shared functions.
Source · Based on the filing body and exhibits
Total Segment Revenue and Segment Profit for Full Fiscal 2023
The company presented recast full-year fiscal year 2023 Total Segment Revenue of $205,091 million and Total Segment Profit of $2,110 million. Full-year segment revenue for Pharmaceutical and Specialty Solutions was $188,820 million, and segment profit was $1,862 million.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…